Birchview Capital LP Acquires Shares of 8,000 Scholar Rock Holding Co. (NASDAQ:SRRK)

Birchview Capital LP acquired a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 8,000 shares of the company's stock, valued at approximately $346,000.

A number of other institutional investors have also modified their holdings of the stock. GAMMA Investing LLC lifted its stake in shares of Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after buying an additional 269 shares during the period. JPMorgan Chase & Co. grew its position in Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock worth $310,000 after purchasing an additional 379 shares during the period. Amalgamated Bank grew its position in Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock worth $114,000 after purchasing an additional 620 shares during the period. Global Retirement Partners LLC grew its position in Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after purchasing an additional 766 shares during the period. Finally, Nisa Investment Advisors LLC grew its position in Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after purchasing an additional 1,031 shares during the period. 91.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, Director Katie Peng sold 1,006 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $34.42, for a total transaction of $34,626.52. Following the completion of the transaction, the director now directly owns 30,319 shares of the company's stock, valued at $1,043,579.98. This trade represents a 3.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tracey Sacco sold 6,500 shares of Scholar Rock stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $33.08, for a total transaction of $215,020.00. Following the completion of the transaction, the insider now directly owns 71,750 shares of the company's stock, valued at $2,373,490. This trade represents a 8.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 255,231 shares of company stock worth $9,220,236 in the last 90 days. 13.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Separately, Wedbush restated an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a research report on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $42.67.

Scholar Rock Price Performance

Shares of NASDAQ:SRRK traded down $0.05 during midday trading on Thursday, hitting $32.86. 530,707 shares of the stock were exchanged, compared to its average volume of 1,253,746. The company has a 50 day moving average price of $32.42 and a 200-day moving average price of $35.72. Scholar Rock Holding Co. has a twelve month low of $6.76 and a twelve month high of $46.98. The stock has a market cap of $3.12 billion, a P/E ratio of -14.03 and a beta of 0.56. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.